Clinigen and Mitsubishi Tanabe Initiate European Managed Access Program for Edaravone to Treat ALS

Clinigen logo

Burton-On-Trent, England, May 22, 2018 / B3C newswire / -- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).

Edaravone is approved for use as a treatment for ALS in Japan, South Korea and the USA.

ALS is an idiopathic neurodegenerative disease in which motor neurons selectively degenerate and vanish. Muscle strength declines throughout the entire body, including the limb, facial, and respiratory muscles, and muscular atrophy progress. The cause for the majority of cases is not well understood, but may involve genetic and environmental factors. It is one of the best known neuromuscular diseases and affects approximately two in 100,000 people worldwide.

John Lagus, Head of Managed Access, Clinigen, said:

“We are pleased to once again be working with MTPC to help eligible patients in Europe gain access to this important medicine.

“As the trusted global leader in access to unlicensed medicines, this partnership aligns with our mission of getting the right medicines to the right patient at the right time.”

Healthcare professionals can obtain details about the edaravone Managed Access Program by calling the medicine access team at +44 1283 494 340, or emailing This email address is being protected from spambots. You need JavaScript enabled to view it.. Access to more information can also be obtained through Cliniport at https://cliniport.co.uk/.


Contacts

Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
John Lagus, Head of Managed Access
+44 (0) 1283 495010

Instinctif Partners
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell
+44 (0) 20 7457 2020
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok